Potential Drug-Drug Interactions With Nirmatrelvir/Ritonavir Among Long-Term Care Facility Residents.
Marzan A Khan, Lori A Daiello, Sarah D Berry and 6 others
PMID 42413156WHAT IT FOUND
85.9% of long-term care residents given nirmatrelvir/ritonavir also received a potentially interacting medication on the same day.
Atorvastatin (28.1%), amlodipine (21.6%), and apixaban (15.9%) were common. This supports medication review, but does not show harm.
Key findings
0185.9% of residents given nirmatrelvir/ritonavir had at least one potentially interacting medication.
0260.9% of residents had at least one treatment day with two or more potentially interacting medications.
03Atorvastatin was the most frequently coadministered potentially interacting medication, given to 28.1% of residents; amlodipine (21.6%) and apixaban (15.9%) were also common.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Potential drug-drug interactions were defined as same-day coadministration, so interactions that extend beyond the same day may have been underestimated. The study did not assess clinical outcomes such as bleeding, arrhythmias, falls, myopathy, or hospitalization. The study could not determine how often clinicians and nursing staff followed recommended treatment guidelines. 6.5% of residents lacked Medicare enrollment data, so demographic information for those residents was missing.
Declared interests
No author conflict-of-interest statement is included in the supplied text. The publication types list NIH extramural research support.
The easy way to misread this
Do not conclude that nirmatrelvir/ritonavir caused adverse events or that interacting medications should be stopped; the study counted same-day coadministration and did not assess clinical outcomes or guideline adherence.